Home/Filings/4/0000059478-23-000079
4//SEC Filing

Van Naarden Jacob 4

Accession 0000059478-23-000079

CIK 0000059478other

Filed

Feb 20, 7:00 PM ET

Accepted

Feb 21, 4:35 PM ET

Size

9.2 KB

Accession

0000059478-23-000079

Insider Transaction Report

Form 4
Period: 2023-02-16
Van Naarden Jacob
EVP & Pres., Lilly Oncology
Transactions
  • Exercise/Conversion

    Common Stock

    2023-02-16+2,78513,159 total
  • Tax Payment

    Common Stock

    2023-02-16$335.01/sh1,314$440,20311,845 total
  • Exercise/Conversion

    Restricted Stock Unit

    2023-02-162,7850 total
    From: 2023-02-16Exp: 2023-02-16Common Stock (2,785 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    4,342
Footnotes (2)
  • [F1]The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the reported securities for purposes of Section 16 or for any other purpose.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

Issuer

ELI LILLY & Co

CIK 0000059478

Entity typeother

Related Parties

1
  • filerCIK 0001661254

Filing Metadata

Form type
4
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 4:35 PM ET
Size
9.2 KB